Vectura Group PLC (VEC) Insider Andrew Derodra Acquires 127 Shares

Vectura Group PLC (LON:VEC) insider Andrew Derodra bought 127 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were purchased at an average price of GBX 118 ($1.60) per share, for a total transaction of £149.86 ($203.23).

Andrew Derodra also recently made the following trade(s):

  • On Friday, December 8th, Andrew Derodra bought 153 shares of Vectura Group stock. The shares were purchased at an average price of GBX 98 ($1.33) per share, for a total transaction of £149.94 ($203.34).
  • On Wednesday, November 8th, Andrew Derodra acquired 156 shares of Vectura Group stock. The shares were bought at an average cost of GBX 96 ($1.30) per share, with a total value of £149.76 ($203.09).

Vectura Group PLC (LON:VEC) opened at GBX 115.40 ($1.56) on Thursday. Vectura Group PLC has a fifty-two week low of GBX 86.50 ($1.17) and a fifty-two week high of GBX 166.97 ($2.26).

VEC has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Vectura Group from GBX 180 ($2.44) to GBX 175 ($2.37) and set an “overweight” rating for the company in a report on Friday, November 10th. Peel Hunt reaffirmed a “hold” rating and set a GBX 160 ($2.17) price objective on shares of Vectura Group in a report on Thursday, November 9th. Panmure Gordon reaffirmed a “buy” rating and set a GBX 150 ($2.03) price objective on shares of Vectura Group in a report on Thursday, November 9th. Numis Securities cut their price objective on shares of Vectura Group from GBX 205 ($2.78) to GBX 170 ($2.31) and set a “buy” rating for the company in a report on Thursday, November 9th. Finally, Royal Bank of Canada raised shares of Vectura Group to a “sector performer” rating and set a GBX 119 ($1.61) price objective for the company in a report on Thursday, December 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Vectura Group currently has an average rating of “Buy” and a consensus price target of GBX 174 ($2.36).

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/18/vectura-group-plc-vec-insider-andrew-derodra-acquires-127-shares.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Insider Buying and Selling by Quarter for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply